Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma-Reference-Cited by-同舟云学术

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma

Published:2019-11-10 Issue:3 Volume:33 Page:498-506
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res

Author:

Reijers Irene L. M.¹²,Rozeman Elisa A.¹²^ORCID,Wilgenhof Sofie¹,Thienen Johannes V.¹,Haanen John B. A. G.¹²,Blank Christian U.¹²

Affiliation:

1. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

2. Division of Molecular Oncology & Immunology The Netherlands Cancer Institute Amsterdam The Netherlands

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcmr.12835

Reference33 articles.

1. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

2. The impact of patient characteristics and disease‐specific factors on first‐line treatment decisions for BRAF‐mutated melanoma: Results from a European expert panel study;Ascierto P. A.;Melanoma Research,2018

3. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

4. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

5. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation;International Journal of Molecular Sciences;2023-09-07

2. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial;European Journal of Cancer;2023-09

3. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned;Current Oncology Reports;2023-03-30

4. Treatment of Recurrent Melanoma Following Adjuvant Therapy;American Journal of Clinical Dermatology;2023-03-08

5. The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study;Cancers;2022-04-21